A Canadian company that provides healthcare support services including medical device reinbursement, payment reimbursement solutions, and patient choice programs has received a $17 million investment to help scale up its successful business lines.

STI Technologies, a company founded in 2001 that has expanded from drug-sampling programs to a variety of services within the Canadian healthcare industry, received the investment from Toronto-based Imperial Capital. STI's biggest growth factors, a card-based drug benefit program called innoviCares, gives patients choices between generic and branded medications.

STI's full portfolio of services includes card-enabled intelligent reimbursement solutions drug sampling, medical device reimbursement, patient assistance, patient choice programs, data, analytics, and medication adherence.

Imperial Capital has now made four healthcare investments within North America in the last five years.